SCHEMBL4638629

SCHEMBL4638629

COCNC(=O)c1ncn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1cccnc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.44
HCRTR2 O43614 1/20 0.44
IDH1 O75874 1/20 0.41
KDR P35968 2/20 0.40
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 2/20 0.39
GAA P10253 2/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KCNH2 Q12809 1/20 0.38
TACR1 P25103 4/20 0.38
TP53 P04637 1/20 0.37
EGFR P00533 1/20 0.37
FGFR1 P11362 1/20 0.37
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
DYRK1A Q13627 1/20 0.36
CFTR P13569 1/20 0.36
NTRK1 P04629 1/20 0.36
GRIN1 Q05586 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4637930 0.90 TACR1 (0.43) KDM4EALDH1A1GAAHTTSMN1; SMN2
SCHEMBL4637994 0.88 CFTR (0.43) HCRTR1HCRTR2IDH1KDRKDM4E
SCHEMBL4637772 0.84 IDH1 (0.51) HCRTR1HCRTR2IDH1KDRKDM4E
SCHEMBL4638108 0.83 GPBAR1 (0.39) HCRTR1HCRTR2KDRTACR1
SCHEMBL4638859 0.77 SMN1; SMN2 (0.43) KDM4EALDH1A1GAAHTTSMN1; SMN2
SCHEMBL4638577 0.74 IDH1 (0.41) IDH1KDRSMN1; SMN2NTRK1GRIN2B
SCHEMBL4639418 0.74 GRIN2B (0.40) KDRKDM4ESMN1; SMN2DYRK1AGRIN1
SCHEMBL4637805 0.73 GAA (0.52) KDM4EALDH1A1GAAHTTSMN1; SMN2
SCHEMBL4637999 0.73 IDH1 (0.46) HCRTR1HCRTR2IDH1KDRKDM4E
SCHEMBL4639437 0.72 TACR1 (0.43) ALDH1A1GAATACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501808-B1 TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-07-02 EP disclosed
US-7179804-B2 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2007-02-20 US disclosed
US-20050239776-A1 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2005-10-27 US disclosed
EP-1501808-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
WO-2003091227-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239776-A1 Tachykinin receptor antagonists TACR2, TACR1, PROKR1 HCRTR1 159/4885HCRTR2 205/4885IDH1 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.